Top-Rated StocksTop-RatedNASDAQ:RGNX REGENXBIO (RGNX) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free RGNX Stock Alerts $15.90 +0.26 (+1.66%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$15.52▼$16.2850-Day Range$15.64▼$24.6152-Week Range$11.83▼$28.80Volume360,158 shsAverage Volume725,076 shsMarket Capitalization$779.74 millionP/E RatioN/ADividend YieldN/APrice Target$38.45 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get REGENXBIO alerts: Email Address REGENXBIO MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside141.9% Upside$38.45 Price TargetShort InterestBearish8.05% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.66Based on 8 Articles This WeekInsider TradingSelling Shares$1.22 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.98) to ($3.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.67 out of 5 starsMedical Sector87th out of 910 stocksBiological Products, Except Diagnostic Industry8th out of 153 stocks 4.4 Analyst's Opinion Consensus RatingREGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageREGENXBIO has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.05% of the outstanding shares of REGENXBIO have been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in REGENXBIO has recently decreased by 4.82%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldREGENXBIO does not currently pay a dividend.Dividend GrowthREGENXBIO does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreREGENXBIO has received a 71.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for REGENXBIO is -0.82. Previous Next 2.6 News and Social Media Coverage News SentimentREGENXBIO has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for REGENXBIO this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for RGNX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,217,370.00 in company stock.Percentage Held by Insiders13.13% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for REGENXBIO are expected to grow in the coming year, from ($3.98) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of REGENXBIO is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of REGENXBIO is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioREGENXBIO has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy About REGENXBIO Stock (NASDAQ:RGNX)REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Read More RGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGNX Stock News HeadlinesApril 19, 2024 | insidertrades.comKenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) StockApril 19, 2024 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Stock Price Down 3.1% Following Insider SellingApril 23, 2024 | Whats On Finance (Ad)Putin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. April 17, 2024 | finance.yahoo.comREGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measuresApril 14, 2024 | americanbankingnews.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at Stifel NicolausApril 12, 2024 | markets.businessinsider.comWhere Regenxbio Stands With AnalystsMarch 31, 2024 | benzinga.comRegenxbio Stock (NASDAQ:RGNX), Quotes and News SummaryMarch 28, 2024 | finance.yahoo.comREGENXBIO Sees Positive Results For Macular Degeneration TherapyApril 23, 2024 | Whats On Finance (Ad)Putin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. March 28, 2024 | prnewswire.comREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDMarch 27, 2024 | finance.yahoo.comREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysMarch 18, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 SharesMarch 12, 2024 | bizjournals.comRockville biotech raises $140M following layoffs, program cutsMarch 11, 2024 | seekingalpha.comRegenxbio: DMD Program Lends Additional Credibility To NAV Technology PlatformMarch 11, 2024 | realmoney.thestreet.comRegenxbio initiated with bullish view at H.C. Wainwright, here's whyMarch 11, 2024 | prnewswire.comREGENXBIO to Participate in Upcoming Investor ConferencesMarch 8, 2024 | realmoney.thestreet.comRBC Capital gets more bullish on Regenxbio, upgrades sharesMarch 8, 2024 | realmoney.thestreet.comRBC Capital upgrades Regenxbio to Outperform, sees positive risk-rewardMarch 8, 2024 | msn.comRegenxbio raised to Buy at RBC on pivot to DuchenneMarch 8, 2024 | markets.businessinsider.comThis Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIOMarch 8, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 SharesMarch 7, 2024 | finance.yahoo.comBearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimatesMarch 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: RegenXBio (RGNX), Biomea Fusion (BMEA)March 6, 2024 | prnewswire.comREGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded WarrantsMarch 6, 2024 | benzinga.comLatest News for Regenxbio Stock (NASDAQ:RGNX)March 6, 2024 | realmoney.thestreet.comLeerink gets more bullish on Regenxbio, upgrades sharesMarch 6, 2024 | realmoney.thestreet.comLeerink more bullish on Regenxbio, upgrades to OutperformSee More Headlines Receive RGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/23/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:RGNX CUSIPN/A CIK1590877 Webwww.regenxbio.com Phone(240) 552-8181FaxN/AEmployees344Year FoundedN/APrice Target and Rating Average Stock Price Target$38.45 High Stock Price Target$55.00 Low Stock Price Target$21.00 Potential Upside/Downside+145.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($6.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,490,000.00 Net Margins-291.99% Pretax Margin-292.15% Return on Equity-68.18% Return on Assets-39.95% Debt Debt-to-Equity RatioN/A Current Ratio2.57 Quick Ratio2.57 Sales & Book Value Annual Sales$90.24 million Price / Sales8.50 Cash FlowN/A Price / Cash FlowN/A Book Value$7.09 per share Price / Book2.21Miscellaneous Outstanding Shares49,040,000Free Float42,604,000Market Cap$766.99 million OptionableOptionable Beta1.29 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Kenneth T. Mills (Age 49)President, CEO & Director Comp: $1.02MMr. Vittal K. Vasista (Age 56)Executive VP & CFO Comp: $671.41kMr. Curran M. Simpson M.S. (Age 62)Executive VP & COO Comp: $677.7kDr. Olivier Danos Ph.D. (Age 66)Executive VP & Chief Scientific Officer Comp: $728.06kDr. Stephen Pakola M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $673.76kMr. Patrick J. Christmas II (Age 53)J.D., Executive VP & Chief Legal Officer Comp: $1.11MMs. Shiva G. FritschChief Communications & People OfficerDr. Laura A. Coruzzi J.D. (Age 70)Ph.D., Executive Vice President of Intellectual Property Dr. Ram Palanki Pharm.D. (Age 47)Executive VP of Commercial Strategy & Operations More ExecutivesKey CompetitorsImmaticsNASDAQ:IMTXRelay TherapeuticsNASDAQ:RLAYCARGO TherapeuticsNASDAQ:CRGXCabaletta BioNASDAQ:CABABioCryst PharmaceuticalsNASDAQ:BCRXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 2,678 shares on 4/18/2024Ownership: 0.005%Hennion & Walsh Asset Management Inc.Bought 32,584 shares on 4/17/2024Ownership: 0.217%Kenneth T MillsSold 15,000 sharesTotal: $272,850.00 ($18.19/share)Napatree Capital LLCBought 40,118 shares on 3/26/2024Ownership: 0.090%PNC Financial Services Group Inc.Bought 746 shares on 3/22/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions RGNX Stock Analysis - Frequently Asked Questions Should I buy or sell REGENXBIO stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGNX shares. View RGNX analyst ratings or view top-rated stocks. What is REGENXBIO's stock price target for 2024? 12 Wall Street analysts have issued 12-month target prices for REGENXBIO's shares. Their RGNX share price targets range from $21.00 to $55.00. On average, they expect the company's stock price to reach $38.45 in the next year. This suggests a possible upside of 141.9% from the stock's current price. View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts. How have RGNX shares performed in 2024? REGENXBIO's stock was trading at $17.95 at the start of the year. Since then, RGNX shares have decreased by 11.4% and is now trading at $15.90. View the best growth stocks for 2024 here. When is REGENXBIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our RGNX earnings forecast. How were REGENXBIO's earnings last quarter? REGENXBIO Inc. (NASDAQ:RGNX) issued its earnings results on Tuesday, February, 27th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by $0.16. The biotechnology company had revenue of $22.30 million for the quarter, compared to analyst estimates of $34.01 million. REGENXBIO had a negative trailing twelve-month return on equity of 68.18% and a negative net margin of 291.99%. The firm's revenue for the quarter was down 28.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.38) earnings per share. What ETFs hold REGENXBIO's stock? ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) and WisdomTree BioRevolution Fund (WDNA).Harbor Disruptive Innovation ETF (INNO). What is Ken Mills' approval rating as REGENXBIO's CEO? 3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees. What other stocks do shareholders of REGENXBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ). Who are REGENXBIO's major shareholders? REGENXBIO's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.22%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Allan M Fox, Kenneth T Mills, Kenneth T Mills, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust. View institutional ownership trends. How do I buy shares of REGENXBIO? Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RGNX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
